Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)
Traded Sep 3, 2026 · Filed Sep 8, 2026
On Sep 3, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$286.09 for US$1.43M under a trading plan, leaving 36,514 shares. Filed Sep 8, 2026 (Form 4).
- Sold
- 5,000 shares
- Price
- US$286.09 average (US$283.99 to US$288.98)
- Value
- US$1.43M
- Holding after
- 36,514 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- CLO & Secretary
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | Sale | 300 | US$283.99 | 41,214 | Direct |
| Sep 3, 2026 | Common Stock | Sale | 1,800 | US$285.17 | 39,414 | Direct |
| Sep 3, 2026 | Common Stock | Sale | 2,115 | US$286.36 | 37,299 | Direct |
| Sep 3, 2026 | Common Stock | Sale | 385 | US$287.53 | 36,914 | Direct |
| Sep 3, 2026 | Common Stock | Sale | 400 | US$288.98 | 36,514 | Direct |
Source
Related
- Ligand Pharmaceuticals Incorporated
- Reardon Andrew
- Ligand Pharmaceuticals Incorporated shareholders
- Form 4 · Reardon Andrew · Oct 6, 2026
- Form 4 · Reardon Andrew · Aug 4, 2026
- Form 4 · Reardon Andrew · Jul 6, 2026
- Form 4 · Reardon Andrew · Jun 2, 2026
- Form 4 · Reardon Andrew · May 4, 2026
- Form 4 · Zimmermann Martine · Sep 24, 2026
- Form 4 · Zimmermann Martine · Sep 14, 2026
- Form 4 · Espinoza Octavio · Aug 14, 2026
- Form 4 · Haas Jason · Aug 14, 2026
- Schedule 13G · Invesco Ltd. · Aug 13, 2026